Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Study Identifier:
ALXN2050-MG-201
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN2050
- Drug: Placebo
Date
Apr 2022 - Nov 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 130 Years
Requirements Information
Sex
Female & Male
Age
18 - 130 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN2050
- Drug: Placebo
Date
Apr 2022 - Nov 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 130 Years years
Requirements Information
Protocol Summary
This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gMG).
Safety will be monitored throughout the study.
Trial Locations
Location
Status
Location
Research Site
Phoenix, Arizona, United States, 85028
Status
N/A
Location
Research Site
Aurora, Colorado, United States, 80045
Status
N/A
Location
Research Site
Boca Raton, Florida, United States, 33487
Status
N/A
Location
Research Site
Port Charlotte, Florida, United States, 33952
Status
N/A
Location
Research Site
Tampa, Florida, United States, 33612
Status
N/A
Location
Research Site
Lexington, Kentucky, United States, 40508
Status
N/A